.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Stephan Becker

Marburg/ DE

University Marburg

Further involvements

25/09/2023
14:50 – 15:00 8 Min. 2 Min.
Short Talk
S-2-3
MVA-MERS-S vaccine candidate elicits long-lasting memory B cell response and highly potent cross-neutralizing antibodies against zoonotic merbecoviruses
Immune Prevention and Therapy
25/09/2023
Poster
P-1-38
A combination of direct acting and host-directed antivirals dramatically suppresses SARS-CoV-2 and MERS-CoV replication
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
25/09/2023
Poster
P-1-39
Brain specific immune responses to Nipah- and Ebola virus infection in in-vitro and ex-vivo models
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
25/09/2023
Poster
P-1-40
Establishment and characterization of lethal and non-lethal animal models for Marburg virus
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
26/09/2023
Poster
P-2-55
Generation and in vitro characterization of two recombinant MVA candidate vaccines expressing Marburg virus glycoprotein or nucleoprotein
Tropical and Emerging Infections
26/09/2023
Poster
P-2-62
Corallopyronin A: successful non-GLP in vivo toxicity tests in rat and dog support continued development to first in human trials
Tropical and Emerging Infections
26/09/2023
Poster
P-2-66
Establishment and characterization of two Crimean-Congo hemorrhagic fever virus animal models in mice
Tropical and Emerging Infections
26/09/2023
Poster
P-2-88
The Antiviral Compound Testing Platform (ACTP) and its application to identify broad-spectrum antivirals
Tropical and Emerging Infections
26/09/2023
Poster
P-2-98
Development of a physiologically based biopharmaceutics model for CorA and prediction of human pharmacokinetics and effective dose using enhanced formulation
Tropical and Emerging Infections
26/09/2023
Poster
P-2-101
Diagnostic qRT-PCR as screening assays of antiviral compounds against highly pathogenic RNA viruses
Tropical and Emerging Infections
26/09/2023
Poster
P-2-105
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike induce differential S1- and S2-specific immune responses in humans
Tropical and Emerging Infections
26/09/2023
Poster
P-1-78
Dissecting humoral immune responses to the MVA-MERS-S vaccine candidate using a systems serology approach
Immune Prevention and Therapy
26/09/2023
15:30 – 15:40 8 Min. 2 Min.
Short Talk
S-6-4
The vaccine candidate MVA-MERS-S against Middle East Respiratory Syndrome Coronavirus: safety and immunogenicity results from a randomized-controlled Phase Ib trial
Tropical and Emerging Infections